Regeneron and Intellia to Discover and Develop CRISPR/Cas Therapeutics
Moving forward is Regeneron Pharmaceuticals’ (REGN) strategy based on strong scientific and technological capability that needs no validation by external validators. The quality, i.e., safety and efficacy, of Regeneron’s approved products and the clinical trial outcomes of the firm’s drugs in late phase trials speak for themselves. Good news from the firm is flooding the media.

The most recent news emanated from Regeneron Pharmaceuticals and Intellia Therapeutics, announcing a licensing and collaboration agreement to advance CRISPR/Cas gene . . .